137 results
Page 5 of 7
8-K
EX-99.1
y839sjbni7ezqa9sml72
4 Dec 19
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
7:31am
8-K
EX-99.1
326t10cr1a0 ij2
12 Nov 19
Results of Operations and Financial Condition
6:33am
8-K
EX-99.1
3t0ey
29 Oct 19
Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7:31am
8-K
EX-99.1
82yv0k3gtrt4ksve
16 Aug 19
Results of Operations and Financial Condition
5:18pm
8-K
EX-1.1
vb5zua zi
24 Jul 19
Entry into a Material Definitive Agreement
7:30am
424B5
f08gb6li
24 Jul 19
Prospectus supplement for primary offering
7:02am
8-K
EX-99.1
jnoc yn7l
31 May 19
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
keawzkz 83dmbx4
14 May 19
Results of Operations and Financial Condition
7:31am
424B5
hksly6uq14kuhkk
23 Apr 19
Prospectus supplement for primary offering
9:36pm
8-K
EX-1.1
7pj3mz
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
8-K
EX-4.1
bl65gd
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
8-K
EX-4.2
k504x9mxttp5hmg9
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
PRER14A
mc3i83f7fr trb
12 Apr 19
Preliminary revised proxy
4:03pm
424B5
lcoyd99wxxs1rhrymz0q
29 Mar 19
Prospectus supplement for primary offering
12:00am